Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Assessing Patient Confidence With Biosimilars
Panelists discuss how health care professionals have varying confidence in biosimilars, driven by concerns about efficacy, safety, and interchangeability. Increased education, real-world evidence, professional engagement, transparent regulations, and comprehensive outcome data can help build trust in these alternative biologic treatments.
EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability
EP: 2.The Economic Impact of Biosimilars
EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars
EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars
EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption
EP: 6.Positioning Biosimilars in Clinical Practice
Now Viewing
EP: 7.Assessing Patient Confidence With Biosimilars
EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
EP: 9.The Growing Market for Biosimilars
EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models
EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies
EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability
EP: 13.How the IRA is Reshaping Biosimilar Adoption
EP: 14.Cost Savings Potential Associated With the Use of Biosimilars
EP: 15.Examining the Role of Interchangeability in Clinical Practice
EP: 16.Optimizing the Implementation of Biosimilars Into Formularies
EP: 17.Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars
EP: 18.Working With Policy Makers to Effectively Implement Biosimilars
Video content above is prompted by the following:
- How do you view patient confidence with biosimilars so far? What can be done to increase their confidence in biosimilars?
Related Videos
Related Content
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025Article
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
